Please login to the form below

Not currently logged in
Email:
Password:

opioids

This page shows the latest opioids news and features for those working in and with pharma, biotech and healthcare.

Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment

Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment

SUD). It then followed this up with the approval in December 2018, of reSET-O, for the treatment of Opioid Use Disorder, which it co-markets with Novartis subsidiary Sandoz..

Latest news

More from news
Approximately 17 fully matching, plus 134 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    About 2.5m people have been diagnosed with opioid dependence in the US, and almost one million are receiving treatment. ... New to the opioid dependence treatment market this year is CAM2038, marketed by Camurus, a company headquartered in Lund, Sweden.

  • Pharma deals continue to slide Pharma deals continue to slide

    These companies have been running out of cash and have had to do deals to stay alive.  Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen ... 74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    It has the potential to reduce pain without typical opioid therapy side effects and is in development for topical application in hypersensitivity disorders such as Bladder Pain Syndrome or Chronic Stump

  • How digital content helps HCPs curb opioid abuse through better prescribing decisions How digital content helps HCPs curb opioid abuse through better prescribing decisions

    In fact, a poll of physicians within our digital community found that 64% believe that doctors have a responsibility to help curb opioid abuse. ... And by delivering information concisely and in an engaging format, this approach is having a measurable

  • Deal Watch March 2016 Deal Watch March 2016

    $110. AstraZeneca/ Kyowa Hakko Kirin. Opioid-induced constipation – Moventig. Licence. $70.

More from intelligence
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics